VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) ROCE % : 0.00% (As of Jun. 2008)

View and export this data going back to . Start your Free Trial

What is VioQuest Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. VioQuest Pharmaceuticals's annualized ROCE % for the quarter that ended in Jun. 2008 was 0.00%.

VioQuest Pharmaceuticals ROCE % Historical Data

The historical data trend for VioQuest Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VioQuest Pharmaceuticals ROCE % Chart

VioQuest Pharmaceuticals Annual Data

Trend

Dec98

Dec99

Dec00

Dec01

Dec02

Dec03

Dec04

Dec05

Dec06

Dec07

ROCE %

Get a 7-Day Free Trial

-637.36

-174.52

-205.27

-115.07

VioQuest Pharmaceuticals Quarterly Data
	Sep03	Dec03	Mar04	Jun04	Sep04	Dec04	Mar05	Jun05	Sep05	Dec05	Mar06	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08
ROCE %	Get a 7-Day Free Trial															-2,345.28	-	-	-	-

VioQuest Pharmaceuticals ROCE % Calculation

VioQuest Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2007 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2007 )		(A: Dec. 2006 )		(A: Dec. 2007 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2007 )		(A: Dec. 2006 )		(A: Dec. 2007 )
	=	-8.779	/	( ( (5.828 - 2.988)	+	(1.358 - 5.843) )	/ 2 )
	=	-8.779	/	( (2.84	+	-4.485)	/ 2 )
	=	-8.779	/	-0.8225
	=	1,067.36 %

VioQuest Pharmaceuticals's ROCE % of for the quarter that ended in Jun. 2008 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2008 )		(Q: Mar. 2008 )		(Q: Jun. 2008 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2008 )		(Q: Mar. 2008 )		(Q: Jun. 2008 )
	=	-4.112	/	( ( (0.698 - 3.452)	+	(1.177 - 2.694) )	/ 2 )
	=	-4.112	/	( ( -2.754	+	-1.517 )	/ 2 )
	=	-4.112	/	-2.1355
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2008) EBIT data.

VioQuest Pharmaceuticals (OTCPK:VOQP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

VioQuest Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of VioQuest Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VioQuest Pharmaceuticals Inc (OTCPK:VOQP) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 2287, Minneapolis, MN, USA, 55402

Website

VioQuest Pharmaceuticals Inc is a biopharmaceutical company focused on the acquisition, development and commercialization of clinical stage drug therapies targeting both the molecular basis of cancer and side effects of cancer treatment.

Executives

Mark D Dacko	director, officer: CFO and Secretary	800 NICOLLET MALL SUITE 2690, MINNEAPOLIS MN 55402
Christopher P. Schnittker	officer: V.P. & Chief Financial Officer	29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Brian Lenz	officer: CFO and Treasurer	65 COMMERCE WAY, HACKENSACK NJ 07601
Lau Johnson Yiu Nam	director
Michael Weiser	director	C/O SPACES, SUITE 265, 3350 VIRGINIA STREET, MIAMI FL 33133
Stephen Rocamboli	director, officer: Secretary	C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019
Daniel E Greenleaf	director, officer: President and CEO	C/O NABI BIO PHARMACEUTICALS, 5800 PARK OF COMMERCE BLVD., N.W., BOCA RATON FL 33487
Lester E Lipschutz	10 percent owner	WOLF BLOCK SCHORR AND SOLIS COHEN, 1650 ARCH STREET, PHILADELPHIA PA 19103
David M Tanen	director	TWO RIVER GROUP HOLDINGS, LLC., 689 FIFTH AVENUE, NEW YORK NY 10022

VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) Headlines

No Headlines